Brief: UCB Reports Positive Results From Gemz Phase 3 Study

UCB SA

08/12/2025 06:27

Dec 8 (Reuters) - Ucb SA UCB.BR:

POSITIVE RESULTS FROM GEMZ PHASE 3 STUDY

FENFLURAMINE SIGNIFICANTLY REDUCES COUNTABLE MOTOR SEIZURE FREQUENCY IN CDKL5 DEFICIENCY DISORDER

FENFLURAMINE WAS GENERALLY WELL TOLERATED, WITH NO NEW SAFETY SIGNALS IDENTIFIED

PLANS TO SUBMIT FOR REGULATORY APPROVAL OF FENFLURAMINE  AS SOON AS POSSIBLE

Source text: here

Further company coverage: UCB.BR

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))